This issue has been the subject of much debate and one that is in a rapid course of evolution. Like the long-QT and short-QT syndromes, Brugada syndrome is traditionally thought of as a primary ...

- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...

Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac ...